The VA does not routinely cover platelet-rich plasma injections as a standard benefit for most veterans. PRP remains classified by the VA healthcare system as an experimental or investigational treatment for the majority of musculoskeletal conditions, which means it falls outside the scope of what VA providers typically order or reimburse. This stands in contrast to TRICARE, the military health plan for active-duty service members and their families, which has covered PRP for certain conditions in the private sector without requiring prior authorization. The distinction between these two federal systems confuses many veterans, and the clinical evidence underneath it all is more nuanced than a simple yes-or-no coverage decision suggests.
What the VA’s Clinical Guidelines Actually Say
In July 2020, the VA and the Department of Defense jointly approved a clinical practice guideline for the non-surgical management of hip and knee osteoarthritis, one of the most common conditions for which patients seek PRP. The guideline covers diagnosis, self-management, physical therapy, pharmacotherapy, orthobiologics, and complementary health approaches. The fact that orthobiologics appear in the guideline at all signals that the VA is aware of PRP and similar treatments, but awareness is not the same as endorsement.
A comparison of the VA/DoD 2020 guideline with other major guidelines found that the core treatments recommended across the board are patient education, weight loss for overweight patients, exercise, and self-management programs. Topical anti-inflammatory drugs are strongly recommended for knee osteoarthritis, and oral anti-inflammatories along with steroid injections into the joint are also recommended.1Osteoarthritis and Cartilage Open. Non-surgical management of hip and knee osteoarthritis; comparison of ACR/AF and OARSI 2019 and VA/DoD 2020 guidelines PRP did not receive a strong recommendation in the VA/DoD guideline, and without that level of backing, VA facilities generally do not offer or pay for it. Individual VA medical centers have some discretion in what they provide, but PRP is not part of the standard formulary of covered procedures the way cortisone shots or hyaluronic acid injections are at many facilities.
How TRICARE Differs from the VA
This is where much of the confusion starts. TRICARE, which covers active-duty military personnel, retirees, and their dependents, took a notably different path. Between fiscal year 2020 and fiscal year 2024, TRICARE authorized private-sector reimbursement for outpatient PRP injections specifically for knee osteoarthritis and lateral epicondylitis (commonly known as tennis elbow) without requiring prior authorization. During that period, the number of PRP injections climbed from 657 in the first year to over 4,100 in the most recent year, and the average reimbursement per injection rose from about $670 to roughly $1,760.2Wolters Kluwer / Clinical Orthopaedics and Related Research. How Is Platelet-rich Plasma Utilized by Outpatient Providers When Covered by Insurance Without Need for Preauthorization?
The researchers who studied this TRICARE trend noted that the coverage existed despite what they described as minimal evidence of efficacy for these conditions. About 92% of the injections met TRICARE’s criteria for reimbursement, which means the system was not catching questionable uses through its approval process. The rapid growth in both volume and cost raises questions about what happens when an insurance system covers a treatment without requiring providers to justify it case by case. For veterans enrolled in VA healthcare rather than TRICARE, though, none of this applies directly. The VA operates its own hospitals and clinics with its own coverage rules, and a TRICARE policy does not automatically extend to the VA system.
Medicare and PRP
Medicare, the federal health insurance program for people 65 and older, also does not broadly cover PRP. An analysis of the Medicare database found that between 2010 and 2014, the total number of PRP injections billed to Medicare increased from 249 to 911, with annual charges jumping from about $500,000 to more than $2 million.3PubMed Central. An Analysis of Current Treatment Trends in Platelet-Rich Plasma Therapy in the Medicare Database Those numbers are small relative to the total Medicare population, and many of those billed codes may have been denied or only partially reimbursed. Medicare’s national coverage determination has generally classified PRP as not reasonable and necessary for most indications, though local Medicare contractors have occasionally made exceptions for specific conditions.
This matters for veterans because many older veterans have both VA healthcare and Medicare. If neither system covers PRP, the out-of-pocket cost falls entirely on the patient. Dual-eligible veterans sometimes assume one system will pick up what the other does not, but for a treatment both systems consider investigational, that safety net does not exist.
What PRP Actually Does and Why the Evidence Is Complicated
PRP is made from a patient’s own blood. A blood draw is spun in a centrifuge to concentrate the platelets, which are then injected back into the injured area. The concentrated platelets release growth factors and signaling molecules that can accelerate tissue repair, support wound healing, and recruit stem cells to the injury site. These processes are relevant to bone, cartilage, and muscle recovery, which is why PRP has attracted so much interest in orthopedics.4Cytokine. The regenerative mechanisms of platelet-rich plasma: A review
The problem is that “PRP” is not one standardized product. The platelet concentration, the presence or absence of white blood cells, the activation method, and the volume injected all vary between clinics and even between preparations at the same clinic. Research has shown that the concentration of white blood cells in a PRP preparation changes its biological profile: higher white blood cell counts increase certain growth factors but also raise levels of enzymes that can break down tissue.5Journal of Orthopaedic Science. Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations This variability makes it genuinely hard to compare one PRP study to another, and it helps explain why the clinical evidence remains uneven.
The Evidence for Knee Osteoarthritis
Knee osteoarthritis is the condition with the most PRP research behind it, and the results are more positive than skeptics often assume, though not without caveats. A meta-analysis of randomized controlled trials found that PRP produced clinically meaningful improvements in pain and function compared with placebo at three and six months. The improvements exceeded the threshold that patients can actually feel, which is a higher bar than mere statistical significance.6PubMed Central. PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration
The same meta-analysis found that the platelet concentration matters substantially. High-platelet PRP maintained clinically meaningful pain relief at 12 months, while low-platelet PRP failed to provide a noticeable benefit beyond what placebo offered. Functional outcomes followed a similar pattern: both high- and low-platelet formulations improved function at three and six months, but only the high-platelet group kept those gains through a year of follow-up.6PubMed Central. PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration An earlier double-blind randomized trial also showed that PRP-treated knees improved significantly while saline-treated knees actually got worse over six months.7PubMed. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial
That said, reviews of the broader literature acknowledge that the effectiveness of PRP injections in the knee remains debated, even though most recent publications point toward short-term pain relief.8PubMed Central. Intra-Articular Platelet-Rich Plasma Injections in Knee Osteoarthritis: A Review of Their Current Molecular Mechanisms of Action and Their Degree of Efficacy The lack of standardization across studies, combined with short follow-up periods in many trials, is why organizations like the VA have been reluctant to endorse PRP as a first-line treatment.
Beyond the Knee
Veterans deal with a wide range of musculoskeletal injuries, and PRP research extends to several other joints and tendons. For chronic tennis elbow, a multicenter randomized trial of 230 patients found that PRP-treated patients reported about 72% improvement in pain scores at 24 weeks compared with 56% in the control group, and the success rate was roughly 84% versus 68%.9PubMed. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients The trial used leukocyte-enriched PRP, which again underscores how much the specific formulation matters.
For rotator cuff problems, a common complaint among veterans, the picture is mixed. A systematic review and meta-analysis found that PRP provided better short-term pain relief than corticosteroid injections in the first three to six weeks, with no significant difference between the two at 12 or 24 weeks for pain. However, PRP showed superior functional outcomes at 12 and 24 weeks, suggesting that while it does not necessarily beat steroids for quick pain relief, it may offer more sustained improvement in shoulder function over time.10PubMed Central. Comparative Efficacy of Platelet-Rich Plasma and Corticosteroid Injections for Rotator Cuff Injury Management: A Systematic Review and Meta-Analysis A critical review of PRP use in shoulder conditions recommended PRP for adhesive capsulitis (frozen shoulder) and for augmenting repair of medium to large rotator cuff tears but did not recommend it for subacromial impingement or rotator cuff tears treated non-surgically.11PubMed Central. The role of platelet-rich plasma in shoulder pathologies: a critical review of the literature
What PRP Costs If You Pay Out of Pocket
Since the VA generally will not cover PRP and most private insurers follow a similar stance, the cost falls on the patient in the vast majority of cases. A nationwide study of pricing at top orthopedic hospitals found that PRP injections ranged from $350 to over $2,800 per injection, with a median of $800. Prices were highest in the Northeast.12PubMed Central. There Is Wide Variation in Platelet-rich Plasma Injection Pricing: A United States Nationwide Study of Top Orthopaedic Hospitals A separate survey found a mean cost of about $707, with some outlier clinics charging nearly $5,000.13PubMed Central. The Cost Variability of Orthobiologics
Most patients need more than one injection. A typical course involves two to three injections spaced a few weeks apart, so the total cost can easily reach $1,500 to $3,000 or more. For veterans living on disability income, that is a significant amount, especially for a treatment whose benefits may last months rather than years. Cost-effectiveness analyses have produced sobering results: one study of PRP for rotator cuff repair found that at roughly $128,000 per quality-adjusted life year gained, PRP was not cost-effective for small and medium tears.14PubMed. Platelet-Rich Plasma Reduces Retear Rates After Arthroscopic Repair of Small- and Medium-Sized Rotator Cuff Tears but Is Not Cost-Effective For knee osteoarthritis, a U.S.-based cost-effectiveness model found that going straight to total knee replacement actually produced slightly more quality-adjusted life years at a similar overall cost compared with trying PRP first, from a healthcare payer perspective.15Journal of Bone and Joint Surgery. The Cost-Effectiveness of Platelet-Rich Plasma Injections for Knee Osteoarthritis From a broader societal perspective that accounts for lost work time and other indirect costs, PRP was slightly cheaper, which shows how much the answer depends on which costs you count.
Treatments the VA Does Cover for Joint Pain
If you are a veteran dealing with knee or hip osteoarthritis, the VA has a well-defined set of covered options. The core recommendations across the VA/DoD and other major guidelines include structured exercise programs, patient education, and weight management support. For pain relief, topical anti-inflammatory gels are strongly recommended for knee osteoarthritis, and oral anti-inflammatory medications along with corticosteroid injections into the joint are also standard covered treatments.1Osteoarthritis and Cartilage Open. Non-surgical management of hip and knee osteoarthritis; comparison of ACR/AF and OARSI 2019 and VA/DoD 2020 guidelines
Physical therapy is a cornerstone of VA-covered care and is available at most VA facilities. For veterans whose joint degeneration has progressed beyond what conservative measures can manage, joint replacement surgery is fully covered. Many veterans seeking PRP are trying to delay or avoid surgery, which is a reasonable goal, but the VA’s position is that the evidence does not yet justify PRP as the way to achieve it.
How Injection Technique Affects Outcomes
One underappreciated factor in PRP treatment is how precisely the injection is placed. A randomized controlled trial comparing ultrasound-guided PRP injections with injections placed by feel alone found that ultrasound guidance achieved 100% accuracy in hitting the target, compared with about 69% accuracy for the palpation-guided group. Patients in the ultrasound-guided group had significantly better outcomes for pain, function, and self-reported improvement at six months.16PubMed Central. Does Guidance Technique Influence Success? A Double-Blind Randomized Controlled Trial Comparing the Precision and Efficacy of Image-Guided and Palpation-Guided PRP Therapy for TMJ Disorders This matters because if you are paying out of pocket for PRP outside the VA, asking whether the provider uses image guidance could meaningfully affect your results. A blind injection that misses the target may not deliver any benefit at all, regardless of how good the PRP formulation is.
Regulatory Status of PRP
Part of the reason PRP occupies this gray zone in coverage decisions is its unusual regulatory position. PRP is not classified as a drug by the FDA. Instead, it is regulated as a blood-derived product, which means the FDA oversees the devices used to prepare it (the centrifuge kits) but does not approve or disapprove PRP itself as a therapy for any specific condition.17Physical Medicine and Rehabilitation Clinics of North America. Orthobiologic Techniques for Surgical Augmentation Without FDA approval for specific indications, insurers including the VA have a straightforward justification for calling PRP experimental: there is no FDA-approved label to point to. This regulatory limbo also means there is no standardized preparation protocol, no required platelet concentration threshold, and no mandated quality control for the final injectable product. Two clinics offering “PRP” may be delivering meaningfully different treatments.
Researchers have consistently emphasized that higher-quality trials with longer follow-up periods are needed before PRP can move from investigational to standard-of-care.18PubMed Central. Current Clinical Recommendations for Use of Platelet-Rich Plasma Until that evidence base matures and PRP preparations become more standardized, the VA is unlikely to change course. Veterans who feel strongly that PRP could help their particular condition may want to discuss the option with their VA provider to confirm the current policy at their facility, as there can be variation across the system, but should be prepared for the possibility of paying for it themselves.
When Pursuing PRP Outside the VA Makes Sense
For veterans considering PRP on their own dime, a few practical considerations are worth thinking through. The strongest clinical evidence exists for knee osteoarthritis treated with high-platelet-concentration PRP, so that combination represents the best-supported use case. Chronic tennis elbow also has reasonably good trial data behind it. For other conditions, the evidence thins out considerably, and you would essentially be paying for an experiment on yourself.
If you decide to proceed, look for a provider who uses a validated commercial PRP preparation system rather than a generic centrifuge, who can tell you the approximate platelet concentration of the final product, and who performs injections under ultrasound or fluoroscopic guidance. These factors are not marketing gimmicks; they correspond to real differences in outcomes seen in the research. Veterans with service-connected disabilities who receive VA disability compensation can spend that money however they choose, including on PRP, but should weigh the cost against the duration of benefit. Even in the best-case scenario, PRP for knee osteoarthritis appears to provide meaningful improvement for roughly six to twelve months, after which many patients need repeat injections or eventually proceed to surgery anyway.